|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2015
|
|
gptkbp:ATCCode
|
gptkb:L04AC10
|
|
gptkbp:brand
|
gptkb:Cosentyx
|
|
gptkbp:CASNumber
|
875356-43-7
|
|
gptkbp:contraindication
|
hypersensitivity to secukinumab
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:hasMolecularFormula
|
C6588H10152N1756O2046S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
secukinumab
|
|
gptkbp:immunoglobulinType
|
gptkb:IgG1_kappa
|
|
gptkbp:indication
|
non-radiographic axial spondyloarthritis
active psoriatic arthritis
moderate to severe plaque psoriasis
active ankylosing spondylitis
|
|
gptkbp:legalStatus
|
gptkb:Rx-only_(EU)
prescription only
Rx-only (US)
Rx-only (Canada)
S4 (Australia)
Rx-only (Japan)
Rx-only (New Zealand)
Rx-only (Switzerland)
Rx-only (UK)
|
|
gptkbp:mechanismOfAction
|
inhibits IL-17A
|
|
gptkbp:molecularWeight
|
147000 Da
|
|
gptkbp:monoclonalAntibodyType
|
fully human
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
gptkb:B1_(AU)
B (US)
B1 (Australia)
|
|
gptkbp:prescribes
|
adults
children (for some indications)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
diarrhea
headache
upper respiratory tract infection
nasopharyngitis
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:interleukin-17A
|
|
gptkbp:UNII
|
45Y7D6D81C
|
|
gptkbp:usedFor
|
gptkb:psoriatic_arthritis
ankylosing spondylitis
plaque psoriasis
non-radiographic axial spondyloarthritis
|
|
gptkbp:bfsParent
|
gptkb:Cosentyx
|
|
gptkbp:bfsLayer
|
5
|